Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282399 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
A Phase 1 study, sponsored by Eisai.
- Terminated
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00282399 is a Phase 1 study that was terminated before completion, run by Eisai. The registered enrollment target is 41 participants.
The verdict
NCT00282399, a Phase 1 study, was terminated before completion, sponsored by Eisai.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study was to determine which of the doses of decitabine maximizes genomic demethylation in patients with Myelodysplastic Syndrome (MDS).
Interventions
- DRUG Subcutaneous Decitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282399
The ClinicalTrials.gov registry entry for NCT00282399 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Subcutaneous Decitabine is the first listed.
NCT00282399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00282399 about?
NCT00282399 is a clinical study titled "A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome". The purpose of this study was to determine which of the doses of decitabine maximizes genomic demethylation in patients with Myelodysplastic Syndrome (MDS).
What is the current status of trial NCT00282399?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2006-10. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00282399?
The interventions under investigation include: Subcutaneous Decitabine (DRUG).
Who is sponsoring clinical trial NCT00282399?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.